This report shares Capgemini perspective of the particularities of genAI and LLM in healthcare, shares the state-of-the-art use cases in the field of innovation, practice and cost related to care within the boundaries of a desirable future where patient superior interest is at the very center.
"Generative AI (GenAI) and Large Language Models (LLMs) have been there over several years but their massive adoption has taken the world by surprise, creating a tidal wave of expectations. Its adoption by the general public has been massive and unprecedented, with chatGPT reaching the 100 million users bar in the space of three months only.
It is estimated that 50% of activities could be supported by AI by 2045, to which genAI will most probably heavily contribute. In healthcare in particular, defined as Life Sciences (Pharma, Biotech, MedTech), Care (hospital, general practice, specialist center) and Insurance (public and private coverage), it is now acknowledged that AI and its more recent form genAI – as opposed to the traditional “discriminative AI” - will revolutionize the domain, which goes together with an imperative to ensure its development and deployment keep patients' interests and safety at the core.
GenAI has the potential to disrupt the Life Sciences industry, particularly in drug discovery, where it shortens cycles, maximize probability of success and tailors treatments for ultra-personalized medicine. NVIDIA, with the launch of its dedicated cloud services BioNeMo, has placed a big ticket in that space. GenAI also introduces efficiency in medical, legal and regulator affairs through automated content generation and sales by leveraging Copilot companions. Additionally, it brings incremental improvements across the value chain, enhancing efficiency in clinical development or operations. Looking ahead, GenAI signals a shift for pharmaceutical companies towards a unique blend of therapy and technology, fostering collaboration with a broad ecosystem made of pure techs, academics, and startups."